GENPREX (GNPX)
(Delayed Data from NSDQ)
$3.11 USD
+0.69 (28.51%)
Updated May 31, 2024 04:00 PM ET
After-Market: $3.52 +0.41 (13.18%) 7:58 PM ET
2-Buy of 5 2
D Value C Growth C Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
GNPX 3.11 +0.69(28.51%)
Will GNPX be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for GNPX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for GNPX
Genprex (GNPX) Expands SCLC Study of Key Candidate, Stock Up
GENPREX (GNPX) Upgraded to Buy: Here's What You Should Know
GNPX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Genprex (GNPX) Up on Advancing Early-Stage NSCLC Study
Other News for GNPX
12 Health Care Stocks Moving In Friday's Intraday Session
Genprex to Present at the 2024 BIO International Convention
GNPX Stock Earnings: Genprex Beats EPS for Q1 2024
Genprex’s Promising Clinical Trials and Leadership Drive Buy Rating
Genprex Doses First Patient in Acclaim-3 Clinical Study of Reqorsa® Immunogene Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer